Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Study of US-ATG-F to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients After Allogeneic Stem Cell Transplantation From Unrelated Donors

NCT01295710 is registered in ClinicalTrials.gov with Neovii Biotech as lead sponsor.

NCT NCT01295710
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01295710 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Study of US-ATG-F to Prevent Moderate to Severe Chronic GVHD in Adult Acute Myeloid Leukemia, Acute Lymphoid Leukemia, and Myelodysplastic Syndrome Patients After Allogeneic Stem Cell Transplantation From Unrelated Donors
Lead sponsor
Neovii Biotech
Phase
Phase 3
Overall status
Completed
Start date
October 10, 2011
Completion date
October 15, 2015
Enrollment
260 (actual)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

adult acute lymphoid leukemia, adult acute myeloid leukemia, gvhd, myelodysplastic syndrome